Cargando…
Macrophage Migration Inhibitory Factor Is a Molecular Determinant of the Anti-EGFR Monoclonal Antibody Cetuximab Resistance in Human Colorectal Cancer Cells
Background: The clinical impact of the monoclonal antibody cetuximab targeting the EGFR in colorectal cancer (CRC) is widely recognized. Nevertheless, the onset of cetuximab resistance is a serious issue that limits the effectiveness of this drug in targeted therapies. Unraveling the molecular playe...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826402/ https://www.ncbi.nlm.nih.gov/pubmed/31557914 http://dx.doi.org/10.3390/cancers11101430 |
_version_ | 1783465077193572352 |
---|---|
author | Russo, Rosita Matrone, Nunzia Belli, Valentina Ciardiello, Davide Valletta, Mariangela Esposito, Sabrina Pedone, Paolo Vincenzo Ciardiello, Fortunato Troiani, Teresa Chambery, Angela |
author_facet | Russo, Rosita Matrone, Nunzia Belli, Valentina Ciardiello, Davide Valletta, Mariangela Esposito, Sabrina Pedone, Paolo Vincenzo Ciardiello, Fortunato Troiani, Teresa Chambery, Angela |
author_sort | Russo, Rosita |
collection | PubMed |
description | Background: The clinical impact of the monoclonal antibody cetuximab targeting the EGFR in colorectal cancer (CRC) is widely recognized. Nevertheless, the onset of cetuximab resistance is a serious issue that limits the effectiveness of this drug in targeted therapies. Unraveling the molecular players involved in cancer resistance is the first step towards the identification of alternative signaling pathways that can be targeted to circumvent resistance mechanisms restoring the efficacy of therapeutic treatments in a tailored manner. Methods: By applying a nanoLC-MS/MS TMT isobaric labeling-based approach, we have delineated a molecular hallmark of cetuximab-resistance in CRC. Results: We identified macrophage migration inhibitory factor (MIF) as a molecular determinant capable of triggering cancer resistance in sensitive human CRC cells. Blocking the MIF axis in resistant cells by a selective MIF inhibitor restores cell sensitivity to cetuximab. The combined treatment with cetuximab and the MIF inhibitor further enhanced cell growth inhibition in CRC resistant cell lines with a synergistic effect depending on inhibition of key downstream effectors of the MAPK and AKT signaling pathways. Conclusions: Collectively, our results suggest the association of MIF signaling and its dysregulation to cetuximab drug resistance, paving the way to the development of personalized combination therapies targeting the MIF axis. |
format | Online Article Text |
id | pubmed-6826402 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-68264022019-11-18 Macrophage Migration Inhibitory Factor Is a Molecular Determinant of the Anti-EGFR Monoclonal Antibody Cetuximab Resistance in Human Colorectal Cancer Cells Russo, Rosita Matrone, Nunzia Belli, Valentina Ciardiello, Davide Valletta, Mariangela Esposito, Sabrina Pedone, Paolo Vincenzo Ciardiello, Fortunato Troiani, Teresa Chambery, Angela Cancers (Basel) Article Background: The clinical impact of the monoclonal antibody cetuximab targeting the EGFR in colorectal cancer (CRC) is widely recognized. Nevertheless, the onset of cetuximab resistance is a serious issue that limits the effectiveness of this drug in targeted therapies. Unraveling the molecular players involved in cancer resistance is the first step towards the identification of alternative signaling pathways that can be targeted to circumvent resistance mechanisms restoring the efficacy of therapeutic treatments in a tailored manner. Methods: By applying a nanoLC-MS/MS TMT isobaric labeling-based approach, we have delineated a molecular hallmark of cetuximab-resistance in CRC. Results: We identified macrophage migration inhibitory factor (MIF) as a molecular determinant capable of triggering cancer resistance in sensitive human CRC cells. Blocking the MIF axis in resistant cells by a selective MIF inhibitor restores cell sensitivity to cetuximab. The combined treatment with cetuximab and the MIF inhibitor further enhanced cell growth inhibition in CRC resistant cell lines with a synergistic effect depending on inhibition of key downstream effectors of the MAPK and AKT signaling pathways. Conclusions: Collectively, our results suggest the association of MIF signaling and its dysregulation to cetuximab drug resistance, paving the way to the development of personalized combination therapies targeting the MIF axis. MDPI 2019-09-25 /pmc/articles/PMC6826402/ /pubmed/31557914 http://dx.doi.org/10.3390/cancers11101430 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Russo, Rosita Matrone, Nunzia Belli, Valentina Ciardiello, Davide Valletta, Mariangela Esposito, Sabrina Pedone, Paolo Vincenzo Ciardiello, Fortunato Troiani, Teresa Chambery, Angela Macrophage Migration Inhibitory Factor Is a Molecular Determinant of the Anti-EGFR Monoclonal Antibody Cetuximab Resistance in Human Colorectal Cancer Cells |
title | Macrophage Migration Inhibitory Factor Is a Molecular Determinant of the Anti-EGFR Monoclonal Antibody Cetuximab Resistance in Human Colorectal Cancer Cells |
title_full | Macrophage Migration Inhibitory Factor Is a Molecular Determinant of the Anti-EGFR Monoclonal Antibody Cetuximab Resistance in Human Colorectal Cancer Cells |
title_fullStr | Macrophage Migration Inhibitory Factor Is a Molecular Determinant of the Anti-EGFR Monoclonal Antibody Cetuximab Resistance in Human Colorectal Cancer Cells |
title_full_unstemmed | Macrophage Migration Inhibitory Factor Is a Molecular Determinant of the Anti-EGFR Monoclonal Antibody Cetuximab Resistance in Human Colorectal Cancer Cells |
title_short | Macrophage Migration Inhibitory Factor Is a Molecular Determinant of the Anti-EGFR Monoclonal Antibody Cetuximab Resistance in Human Colorectal Cancer Cells |
title_sort | macrophage migration inhibitory factor is a molecular determinant of the anti-egfr monoclonal antibody cetuximab resistance in human colorectal cancer cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826402/ https://www.ncbi.nlm.nih.gov/pubmed/31557914 http://dx.doi.org/10.3390/cancers11101430 |
work_keys_str_mv | AT russorosita macrophagemigrationinhibitoryfactorisamoleculardeterminantoftheantiegfrmonoclonalantibodycetuximabresistanceinhumancolorectalcancercells AT matronenunzia macrophagemigrationinhibitoryfactorisamoleculardeterminantoftheantiegfrmonoclonalantibodycetuximabresistanceinhumancolorectalcancercells AT bellivalentina macrophagemigrationinhibitoryfactorisamoleculardeterminantoftheantiegfrmonoclonalantibodycetuximabresistanceinhumancolorectalcancercells AT ciardiellodavide macrophagemigrationinhibitoryfactorisamoleculardeterminantoftheantiegfrmonoclonalantibodycetuximabresistanceinhumancolorectalcancercells AT vallettamariangela macrophagemigrationinhibitoryfactorisamoleculardeterminantoftheantiegfrmonoclonalantibodycetuximabresistanceinhumancolorectalcancercells AT espositosabrina macrophagemigrationinhibitoryfactorisamoleculardeterminantoftheantiegfrmonoclonalantibodycetuximabresistanceinhumancolorectalcancercells AT pedonepaolovincenzo macrophagemigrationinhibitoryfactorisamoleculardeterminantoftheantiegfrmonoclonalantibodycetuximabresistanceinhumancolorectalcancercells AT ciardiellofortunato macrophagemigrationinhibitoryfactorisamoleculardeterminantoftheantiegfrmonoclonalantibodycetuximabresistanceinhumancolorectalcancercells AT troianiteresa macrophagemigrationinhibitoryfactorisamoleculardeterminantoftheantiegfrmonoclonalantibodycetuximabresistanceinhumancolorectalcancercells AT chamberyangela macrophagemigrationinhibitoryfactorisamoleculardeterminantoftheantiegfrmonoclonalantibodycetuximabresistanceinhumancolorectalcancercells |